AstraZeneca Enhances Drug Discovery with Pelago Bioscience's CETSA® Assay

5 Jul 2024

Pelago Bioscience offers high-throughput screening service based on CETSA® - a transformative, label-free assay for target engagement quantification in physiologically relevant context. In this case study, the CETSA® assay has been exemplified with AstraZeneca's screening of 500,000 compounds on a protein target, demonstrating superior hit rates and a six-month time-saving advantage.

Primary Screening with CETSA

Pelago Bioscience

Primary screening based on Cellular Thermal Shift Assay (CETSA) allows for rapid identification of high quality chemical starting points against the native, full-length protein in live cells. 

(0)

Links

Tags

Compound AnalysisCompound analysis is used to discover specific compounds that could be promising candidates for pharmaceutical use. This potential is identified when compounds have the desired effect, such as interaction with a target protein, during high throughput screening.Label-Free Analysis
AstraZeneca Enhances Drug Discovery with Pelago Bioscience's CETSA® Assay